Kornimate/medical-research-clean huggingface dataset:
post stroke aphasia rehabilitation using computer-based arabic software program: a randomized control trial

Conditions: Aphasia Rehabilitation

Summary: aphasia is a disorder of language processing caused by a lesion in particular brain regions. treatment aims at improving or restoring impaired function or at compensating for deficits. more recently, computer technology has been integrated into treatment options. in this study, a detailed and comprehensive computerized software program for aphasia rehabilitation is designed for the treatment of arabic speaking egyptian aphasic patients. aim of the study: design a computerized software program for the rehabilitation of arabic speaking egyptian aphasic patients.

aphasia is a disorder of language processing caused by a lesion in particular brain regions. treatment aims at improving or restoring impaired function or at compensating for deficits. more recently, computer technology has been integrated into treatment options. in this study, a detailed and comprehensive computerized software program for aphasia rehabilitation is designed for the treatment of arabic speaking egyptian aphasic patients. aim of the study: design a computerized software program for the rehabilitation of arabic speaking egyptian aphasic patients. subjects: the study was conducted on 50 patients with aphasia who attend the unit of phoniatrics during the period of one year, department of otorhinolaryngology, alexandria main university hospitals. methodology: the training materials were designed as a software program. each patient was subjected to assessment before and after the application of the rehabilitation program. patients were randomized into two groups: group i who received therapy using the software aphasia rehabilitation program and group ii who received conventional (traditional) language therapy. therapy continued for 48 sessions over six months.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of aphasia * age 18 years or more exclusion criteria: * intellectual disabilities. * visual impairment. * hearing impairment. * associated dysarthria and or apraxia of speech. * associated psychiatric disorders

Keywords: aphasia, post stroke
school based malaria control in ugandan schoolchildren

Conditions: Malaria

Summary: the investigators hypothesize that schoolchildren treated with ipt using dp over one year of follow-up will have a different risk of clinical malaria compared to those treated with placebo.


Eligibility criteria:
inclusion criteria: * age ≥ 6 - 14 years * pupils enrolled at participating school * willingness of the parent/guardian to provide consent * provision of assent by pupil (those above 8 years) exclusion criteria: * known allergy or history of adverse reaction to study medications * intention of changing of schools during the follow-up period * history (obtained from the parent/guardian) of any known serious chronic disease requiring frequent medical care

Keywords: malaria
international orthopaedic multicenter study in fracture care (inormus)

Conditions: Fractures or Dislocations

Summary: background: worldwide, injuries from trauma represent a major public health problem. the world health organization (who) has deemed this problem as one of the most important global priorities, calling 2011-2020 the 'decade of action for road safety'. despite this, there is little empirical data in low and middle-income countries quantifying the burden of musculoskeletal injuries. methods: inormus is a global, prospective, multi-center, observational cohort study. the primary objective of the study is to determine the mortality, re-operation and infection rates of musculoskeletal trauma patients within 30 days post-hospital admission. the inormus study seeks to enroll 40,000 patients from low-middle income countries in africa, asia, and latin america.

number of participants: 40,000 primary research objectives: to determine among adult individuals admitted to hospital with musculoskeletal trauma (e.g. fractures or dislocations): 1. the incidence of major complications (mortality, re-operation and infection) as a composite outcome and the components of the composite within 30 days post-hospital admission. 2. the factors (system and patient variables) associated with the composite of major complications (mortality, re-operation and infection) within 30 days post-hospital admission. secondary research objective: to determine the rates of major complications within 30 days post-hospital admission by type of fracture treatment provided (e.g. splinting versus operative fixation) and admission to hospital time (e.g. \ 72 hours). diagnosis and main inclusion criteria: this study has minimal exclusion criteria by design. all patients 18 years of age or older admitted to a recruiting hospital for treatment of an orthopaedic injury that occurred within 3 months will be eligible for participation. patients who are diagnosed with an orthopaedic fracture, dislocation, or fracture dislocation of the appendicular skeleton or spine will be included. study outcomes: the primary outcome is a composite of mortality, mortality, re-operation and infection within 30 days from hospital admission for all research objectives. duration of patient follow-up: study participants will be followed until 30 days post hospital admission.

Eligibility criteria:
inclusion criteria: * patients 18 years of age or older * admitted to a recruiting hospital for treatment of an orthopaedic injury * injury occurred within 3 months of hospital admission * patients diagnosed with an orthopaedic fracture, dislocation, or fracture dislocation of the appendicular skeleton or spine will be included.

Keywords: fractures burden of fractures orthopaedic fractures orthopaedic injuries orthopaedic trauma observational study outcomes of fracture care epidemiology
effectiveness of family-professional collaboration on functional goals achievement of children with cerebral palsy and caregivers' quality of life and burden

Conditions: Cerebral Palsy; Collaborative Intervention Process; Functional Goals Achievement

Summary: the aim of this study is to examine the effect of implanting the family-professional collaboration practice model on the functional goals achievement of children with cp and their caregivers' quality of life and burden. the children will be treated by physical therapists who will be assigned to two groups (control and experimental).

a randomized, single-blinded control study involved 28 physical therapists and 44 pairs of children with cp aged 2-12 years old and their caregivers will be assigned randomly into experimental and control groups. physical therapists in the experimental group will receive two instructional sessions (3 hours each) to implement collaboration during the therapy sessions and physical therapists in the control group will receive no instructions. children will receive 45- 60 minutes therapy sessions (5 sessions/week) for six weeks. goal attainment scaling (gas) to measure the children's goals achievement change rate, the arabic version of the world health organization quality of life brief (whoqol- brief) to examine the caregivers' quality of life, and the zarit burden interview arabic abridged version (zbi-a) to evaluate the caregivers' burden will be used.

Eligibility criteria:
inclusion criteria: * physical therapists with at least one year of experience in pediatric physical therapy. * children with cp, aged between 2 to 12 years, gross motor function classification system (gmfcs) level i, ii, and iii, and attended the physical therapy sessions accompanied by their caregivers. exclusion criteria: * physical therapists in the experimental group who rate their level of confidence to implement the collaborative strategies less than 4 out of 5. * children who underwent recent surgery (6 months) or after botulinum toxin injection treatment (3 months), had uncontrolled seizure disorder, or discontinued physical therapy sessions.

Keywords: family-professional collaboration partnerships children's performance quality of life burden caregivers physical therapists
study of xl647 in subjects with non-small-cell lung cancer

Conditions: Non-small-cell Lung Cancer

Summary: the purpose of this phase ii study is to determine the safety, tolerability, and activity of xl647 in previously untreated subjects with non-small cell lung cancer (nsclc). xl647 is a small molecule that potently inhibits multiple receptor kinases, including egfr, vegfr2 (kdr), erbb2, and ephb4. sensitivity to egfr inhibitors has been linked to specific egfr mutations and associated with certain clinical characteristics in patients with nsclc (eg, female, minimal and remote smoking history, and adenocarcinoma histology).


Eligibility criteria:
inclusion criteria: * subject has nsclc with a histologically confirmed diagnosis of adenocarcinoma with measurable disease (stage iiib, with malignant pleural effusion, and stage iv) and either has a demonstrated activating mutation of the egf receptor in tumor tissue or meets one of three criteria: asian, female, and minimal or no smoking history. * measurable disease defined according to recist * ecog performance status of 0 or 1 * normal organ and marrow function * no other malignancies within 5 years, except for non-melanoma skin cancer exclusion criteria: * radiation to ≥25% of bone marrow within 30 days of xl647 treatment * prior systemic anticancer therapy, including cytotoxic chemotherapy, anti-vegf, anti-vegfr, or anti-egfr agents or investigational drug * subject has not recovered to ≤ grade 1 or to within 10% of baseline values from adverse events due to other medications administered \> 30 days before study enrollment * receiving anticoagulation therapy with warfarin (low-dose warfarin \< 1 mg/day, heparin and low molecular weight heparins are permitted) * the subject meets any of the following cardiac criteria: * corrected qt interval (qtc) of \> 460 msec * family history of congenital long qt syndrome or unexplained sudden death * history of sustained ventricular arrhythmias * has a finding of left bundle branch block * has an obligate pacemaker * has important bradycardia defined as a heart rate of \< 50 bpm due to sinus node dysfunction * has uncontrolled hypertension * has symptomatic congestive heart failure, unstable angina, or a myocardial infarction within the past 3 months * has a serum potassium or serum magnesium level that falls outside the normal range * the subject has progressive symptomatic or hemorrhagic brain or leptomeningeal metastases * uncontrolled intercurrent illness * subject is pregnant or breastfeeding * known hiv
motion clinical trial

Conditions: Osteoarthritis, Knee

Summary: prospective, multicenter, two-arm, 2:1 randomized controlled trial (rct) comparing the benefits in subjects with medial knee osteoarthritis who are treated with either the misha knee system or with non-surgical treatment. this is the first randomized head-to-head study comparing outcomes from subjects treated with the misha knee system.


Eligibility criteria:
key inclusion criteria: 1. activity exacerbated knee pain isolated to the medial compartment and not global in nature 2. womac pain ≥ 40 3. failed to find relief in non-surgical treatment modalities key exclusion criteria: 1. large medial osteophyte(s) or considerable extruded meniscus that may interfere with the placement or function of the device 2. poor bone quality (e.g., bony erosion, osteopenia, osteoporosis) 3. ligamentous instability 4. active or recent knee infection 5. inflammatory joint disease, including sequelae of viral infections 6. suspected or documented allergy or hypersensitivity to cobalt, chromium, nickel or other metals 7. history of keloid, hypertrophic or contracture scaring 8. propensity for restrictive scar formation or adhesions with prior procedures
drug use investigation for lamictal

Conditions: Epilepsy

Summary: the purpose of this study is to grasp actual status of usage of lamotrigine tablet and to collect information for using lamotrigine tablet effectively and safely as well as to grasp onset status of adverse events in pediatric subjects, geriatric subjects, pregnant women, subjects with poor renal and hepatic functions.


Eligibility criteria:
inclusion criteria: * subjects with epilepsy having the following seizure types. * partial seizures (including secondary generalized seizures) * tonic-clonic seizures * generalized seizures of lennox-gastaut syndrome exclusion criteria: - none
hydroxychloroquine and chlorphenesin carbamate in combination with mfolfirinox in pancreatic cancer

Conditions: Pancreatic Cancer

Summary: pancreatic cancer is the 8th most prevalent cancer in korea, and its 5-year overall survival rate has shown less than 10% due to its dismal prognosis. to date, the only curative treatment of pancreatic cancer is surgical resection. however, about 60% of patients with pancreatic cancer have been diagnosed as a locally advanced unresectable or metastatic disease at diagnosis owning to its difficulty in the early detection of cancer. the 5-year survival rate has been reported to be less than 25% even with surgical resection. considering the high rate of metastasis and recurrence, systemic chemotherapy is essential to prolong survival. therefore, using ai platforms of raptor (rna expression-based anti-symmetrical pairing tool for on-demand response) and redrug (restoration using the drug for targeting unbalanced gene) developed by oncocross, chlorphenesin carbamate, and hydroxychloroquine were discovered as candidate drugs having anti-metastatic effects. this study aimed to evaluate the efficacy and safety of hydroxychloroquine and chlorphenesin carbamate in combination with mfolfirinox in patients with inoperable locally advanced or metastatic pancreatic cancer.


Eligibility criteria:
inclusion criteria: 1. adults of age ≥ 19 and \< 80 years 2. a patient who meets any of the following criteria at the time of screening or before, and who is scheduled to receive chemotherapy with modified folfirinox for the first time after screening * locally advanced inoperable pancreatic cancer * metastatic pancreatic cancer 3. one or more measurable lesions by recist v 1.1 4. eastern cooperative oncology group (ecog) performance status (ps) 0 pr 1 5. estimated life expectancy of at least 12 weeks or more at the discretion of the investigator exclusion criteria: 1. history of major surgery within 4 weeks at the time of screening 2. symptomatic, uncontrolled brain metastasis or meningeal carcinomatosis 3. history of malignancy within 5 years at the time of screening 4. history of human immunodeficiency virus (hiv) or active hepatitis 5. active infection requiring systemic antibiotic therapy 6. patients who have maculopathy or are receiving treatment for corneal or retinal disease, or under follow-up 7. history of acute or subacute intestinal obstruction or paralytic ileus, or a history of chronic diarrhea considered clinically significant at the discretion of the investigator 8. serious neurological, psychiatric condition including drug abuse or alcoholism, which would prevent the subject from participating in the study 9. patients with any condition who are considered unsuitable for participation in the study in the judgment of the investigator
subglottic secretions surveillance to predict bacterial pathogens involved in ventilator-associated pneumonia

Conditions: Ventilator-associated Pneumonia

Summary: many studies provide evidence for the benefit of lower respiratory tract surveillance, mostly by culture of endotracheal secretions, to predict bacterial pathogens (especially multi-drugs resistant pathogens) involved in vap. the demeter study (nct02515617) assessing the medico-economical impact of the subglottic secretions drainage (ssd) provides the opportunity to evaluate the accuracy of the subglottic secretions culture surveillance to predict pathogens involved in vap (in comparison with the concomitant endotracheal secretions surveillance). these subglottic and tracheal secretions culture surveillance will be masked to the investigators of the demeter study. this ancillary study will be performed in 14 centers participating to the demeter study


Eligibility criteria:
inclusion criteria: * age over 18 years * invasive mechanical ventilation delivered via an endotracheal tube and expected to be required more than 24 hours * intubation performed in units in which the specific endotracheal tube allowing the subglottic secretions drainage will be available during the ssd period of the trial * information delivered exclusion criteria: * previous inclusion in the study * patients moribund at the intensive care unit admission * pregnant, parturient or breast-feeding woman * patient hospitalized without consent and/or deprived of liberty by court's decision * patient under guardianship or curators * lack of social insurance * concomitant inclusion in a trial on vap prevention * patient with no comprehension of the french language

Keywords: ventilator-associated pneumonia surveillance subglottic-secretions critically ill patients prevention
self-injury treatment and recovery in veterans

Conditions: Self-Injurious Behavior

Summary: nonsuicidal self-injury (nssi) refers to the intentional destruction of one's own body tissue without suicidal intent and for purposes that are not socially sanctioned. while nssi has been understudied among veterans, the lifetime prevalence rate of nssi in veterans is approximately three times higher than the general population. moreover, nssi is associated with increased risk for violence, psychiatric distress, and marked impairment in psychosocial functioning. even though nssi is distinct from suicidal behaviors in several important ways, nssi remains a strong predictor of a future suicide attempt. the primary goal of this project is to evaluate the treatment and acceptability of a brief intervention for nssi that aims to reduce psychosocial impairment and nssi behaviors in veterans.

nonsuicidal self-injury (nssi) refers to the intentional destruction of one's own body tissue without suicidal intent and for purposes that are not socially sanctioned. while nssi has been understudied among veterans, the lifetime prevalence rate of nssi in veterans is approximately three times higher than the general population. moreover, nssi is associated with increased risk for violence, psychiatric distress, and marked impairment in psychosocial functioning. even though nssi is distinct from suicidal behaviors in several important ways, nssi remains a strong predictor of a future suicide attempt. the primary goal of this project is to evaluate the treatment and acceptability of a brief intervention for nssi that aims to reduce psychosocial impairment and nssi behaviors in veterans. this treatment, known as the treatment for self-injurious behaviors (t-sib) incorporates evidence-based approaches to replace nssi with behaviors that improve psychoso ial functioning. a core component of t-sib is functional assessment that identifies the antecedents and consequences of nssi. this project will enhance t-sib by using ecological momentary assessment (ema) to conduct nssi functional assessment in-vivo. ema reduces retrospective recall bias and can increase engagement with therapeutic goals.

Eligibility criteria:
inclusion criteria: * 18 years of age or older * past service in the united states military * nonsuicidal self-injury engagement on 2 occasions in past 30 days * fluent in english * able to provide voluntary informed consent exclusion criteria: * lifetime history of psychosis, mania, or hypomania * imminent risk for suicide/homicide warranting immediate intervention * unable/unwilling to complete study procedures

Keywords: self-injurious behavior veterans
safety and preliminary performance of xtrac o.s. system for lead extraction.

Conditions: Bradycardia

Summary: this is an open label, interventional, feasibility, prospective, multicenter, clinical trial of lead extraction. the xtrac o.s. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach. a total of 15 patients, who are scheduled for cied lead extraction, will be recruited in order to ensure a total of at least 10 patients finishing the study procedures and follow up.


Eligibility criteria:
inclusion criteria: 1. men or female patients, 18-85 years old. 2. patients must understand the procedures and methods of this study and be willing to sign the informed consent form and to complete the trial in strict accordance with clinical trial protocol. 3. scheduled for a cied lead extraction upon current guidelines. 4. lead implant duration more than 1 year and less than 5 years. 5. patient must be sars-cov-2 negative and without covid-19 signs and symptoms, prior to enrollment. 6. patients are classified as asa ii/iii. 7. leads with external diameter of 7fr-9fr. exclusion criteria: 1. patient age \> 85 years old. 2. hemodynamic instability. 3. class iv nyha heart failure. 4. contrast allergy. 5. patients felt to be high risk due to degree of acute illness or systemic comorbidities. 6. patients who are placed on a heparin bridge, and are felt to be high risk for even brief discontinuation of anticoagulation 7. pregnant or lactating. 8. participating in another clinical study. eligibility will be determined by the pi and investigators based on the exclusion/inclusion criteria, current medical status and evaluation of the procedure risks mitigation.
denosumab, teriparatide or both for the treatment of postmenopausal osteoporosis

Conditions: Osteoporosis

Summary: the aim of this study is to determine whether denosumab (an fda-approved osteoporosis therapy), in combination with teriparatide (an fda-approved osteoporosis therapy), will increase bone mineral density more than either one alone in postmenopausal osteoporotic women.


Eligibility criteria:
inclusion criteria: must satisfy a and b and c and d below: * (a) women aged \> 55 * (b) postmenopausal * (c) osteoporotic with high risk of fracture exclusion criteria: * confirmed serum alkaline phosphatase above upper normal limit with no explanation * liver disease (ast or alt \> 2 x upper normal limit). * renal disease (serum creatinine \> 2.0 mg/dl). * hypercalcemia (ca \>10.5 mg/dl) * elevated blood pth (intact pth \> 65 pg/ml) * serum 25-oh vitamin d \< 20 ng/ml * hct \< 32%. * history of malignancy (except basal cell carcinoma) or radiation therapy. * significant cardiopulmonary disease including unstable coronary artery disease, stage d acc/aha heart failure or any other condition that the investigator deems may preclude the subject from participating safely or completing the protocol procedures. * major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures. * excessive alcohol use or substance abuse that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures. * known congenital or acquired bone disease other than osteoporosis (including osteomalacia, hyperparathyroidism, paget's disease) * current use or use in the past 6 months of oral bisphosphonate * current use or use within the past 3 months of estrogens, selective estrogen receptor modulators, or calcitonin. * use of oral or parenteral glucocorticoids for more than 14 days within the past 6 months. * any current or previous use of strontium or any parenteral bisphosphonate. * known sensitivity to mammalian cell-derived drug products. * known sensitivity to teriparatide or any of its excipients.

Keywords: osteoporosis postmenopausal denosumab teriparatide forteo® dxa bone mineral density pqct